Ensure Long-Acting Beta-Agonists Aren't Used Alone for Asthma

February 2018

New evidence will bring up questions about the role of long-acting beta-agonists (LABAs) for asthma.

We've heard about early studies that suggest using a LABA withOUT an inhaled corticosteroid (ICS) increases the risk of asthma death.

This led to Health Canada's warnings in 2005 to stop LABAs once asthma is controlled.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Diabetes Look for New GLP-1 Agonists for Type 2 Diabetes
Monitoring Compare FreeStyle Libre and Other Continuous Glucose Monitors
Women's Health Ease Fears About Breast Cancer Risk With Hormonal Contraception
Natural Health Products Be Aware That Biotin May Skew Lab Test Results
Natural Health Products Watch for Warnings of Liver Damage on Labels of Green Tea Extract Products
Cardiology Use "ABCDs" to Optimize Meds for Stable Coronary Artery Disease
Asthma Ensure Long-Acting Beta-Agonists Aren't Used Alone for Asthma
Travel Medicine Share Strategies to Limit Altitude Sickness
Psoriasis Know Key Points About Biologics for Your Patients With Psoriasis
Nausea & Vomiting Consider Akynzeo for Highly Emetogenic Chemotherapy
Practice Get Tools to Tackle This Flu Season
Practice Advise Patients That Using Expired EpiPen May Be Needed During the Shortage